Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Gregory A. Demopulos, M.D.

Gregory A. Demopulos, M.D.

Chairman and CEO, Omeros Corporation

Appears in 1 story

Notable Quotes

While this decision does not allow us to begin labeling discussions now, it does provide paths forward based on collecting historical data with or without an independent literature review. — On 2022 FDA dispute resolution decision

Stories

First treatment approved for deadly stem cell transplant complication

New Capabilities

Leading company through first commercial launch

For decades, patients who developed transplant-associated thrombotic microangiopathy (TA-TMA) after stem cell transplants faced a grim reality: a life-threatening complication with no approved treatment. Mortality rates for high-risk cases reached 80-90%. In December 2025, the FDA approved Yartemlea, the first therapy for this condition, marking Seattle-based Omeros Corporation's first drug approval after 31 years. The company launched commercially on January 2, 2026, announced pricing at $36,000 per vial on January 7, and by late January both adult and pediatric patients were receiving treatment at transplant centers nationwide.

Updated Apr 23